After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
But there are no efficacy data, and the mechanism has a mountain to climb.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
CRB-601 and PF-06940434 fall by the wayside.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
